ntla-2001
Intellia Therapeutics
['ntla-2001', 'cardiomyopathy', 'cardio', 'crispr', 'intellia']
intellia presents updated interim data from the cardiomyopathy arm of ongoing phase 1 study of ntla-2001, an investigational crispr therapy for the treatment of transthyretin (attr) amyloidosis at the american heart association scientific sessions 2022 
News forum for top stories in Cardiac and Vascular to include cardiovascular, structural heart, PV, EVAR, TAVR, Interventional, neurovascular @PrimeCoreSearch